INTRODUCTION: Immediate empirical antibiotic therapy is mandatory in febrile chemotherapy-induced neutropenia, but its optimal duration is unclear, especially in patients with fever of unknown origin (FUO). OBJECTIVES: The primary objective of this 20-month prospective observational study was to evaluate the feasibility and safety of short-term antibiotic treatment in afebrile or febrile patients exhibiting FUO, irrespective of their neutrophil count. The secondary objective was to describe the epidemiology of all episodes of febrile neutropenia. METHODS: In the first phase of the study, empirical antibiotic therapy in FUO patients was stopped after 48 h of apyrexia, in accordance with European Conference on Infections in Leukaemia guidelines (n = 45). In the second phase of the study, antibiotics were stopped no later than day 5 for all FUO patients, regardless of body temperature or leukocyte count (n = 37). RESULTS: Two hundred and thirty-eight cases of febrile neutropenia in 123 patients were included. Neither the composite endpoint (p = .11), nor each component (in-hospital mortality (p = .80), intensive care unit admission (p = 0.48), relapse of infection ≤48 h after discontinuation of antibiotics (p = .82)) differed between the two FUO groups. Violation of protocol occurred in 17/82 episodes of FUO without any major impact on statistical results. Twenty-six (57.3%) and 22 (59.5%) FUO episodes did not relapse during hospital-stay (p = 1), and nine (20%) and five (13.5%) presented another FUO, respectively. One hundred and fifty-six episodes of febrile neutropenia (65.5%) were clinically or microbiologically documented, including 85 bacteremia. CONCLUSIONS: These results suggest that early discontinuation of empirical antibiotics in FUO is safe for afebrile neutropenic patients.
INTRODUCTION: Immediate empirical antibiotic therapy is mandatory in febrile chemotherapy-induced neutropenia, but its optimal duration is unclear, especially in patients with fever of unknown origin (FUO). OBJECTIVES: The primary objective of this 20-month prospective observational study was to evaluate the feasibility and safety of short-term antibiotic treatment in afebrile or febrile patients exhibiting FUO, irrespective of their neutrophil count. The secondary objective was to describe the epidemiology of all episodes of febrile neutropenia. METHODS: In the first phase of the study, empirical antibiotic therapy in FUO patients was stopped after 48 h of apyrexia, in accordance with European Conference on Infections in Leukaemia guidelines (n = 45). In the second phase of the study, antibiotics were stopped no later than day 5 for all FUO patients, regardless of body temperature or leukocyte count (n = 37). RESULTS: Two hundred and thirty-eight cases of febrile neutropenia in 123 patients were included. Neither the composite endpoint (p = .11), nor each component (in-hospital mortality (p = .80), intensive care unit admission (p = 0.48), relapse of infection ≤48 h after discontinuation of antibiotics (p = .82)) differed between the two FUO groups. Violation of protocol occurred in 17/82 episodes of FUO without any major impact on statistical results. Twenty-six (57.3%) and 22 (59.5%) FUO episodes did not relapse during hospital-stay (p = 1), and nine (20%) and five (13.5%) presented another FUO, respectively. One hundred and fifty-six episodes of febrile neutropenia (65.5%) were clinically or microbiologically documented, including 85 bacteremia. CONCLUSIONS: These results suggest that early discontinuation of empirical antibiotics in FUO is safe for afebrile neutropenicpatients.
Authors: John C O'Horo; Jasmine R Marcelin; Omar M Abu Saleh; Amelia K Barwise; Patricia M Odean; Christina G Rivera; Aaron J Tande; John W Wilson; Douglas R Osmon; Pritish K Tosh Journal: J Oncol Pract Date: 2019-07-19 Impact factor: 3.840
Authors: Risa Fuller; Erin Moshier; Samantha E Jacobs; Douglas Tremblay; Guido Lancman; Alexander Coltoff; Jessica Caro; John Mascarenhas; Meenakshi Rana Journal: Open Forum Infect Dis Date: 2020-04-21 Impact factor: 3.835
Authors: A Schauwvlieghe; A Dunbar; E Storme; A Vlak; R Aerts; J Maertens; B Sciot; T Van Der Wel; G Papageorgiou; I Moors; J J Cornelissen; B J A Rijnders; T Mercier Journal: EClinicalMedicine Date: 2021-04-25
Authors: Jason N Barreto; Samuel L Aitken; Elizabeth M Krantz; Jerod L Nagel; Sanjeet S Dadwal; Susan K Seo; Catherine Liu Journal: Open Forum Infect Dis Date: 2022-02-04 Impact factor: 4.423
Authors: Anke Verlinden; Hilde Jansens; Herman Goossens; Sébastien Anguille; Zwi N Berneman; Wilfried A Schroyens; Alain P Gadisseur Journal: Open Forum Infect Dis Date: 2021-12-23 Impact factor: 3.835
Authors: F A Niessen; M S M van Mourik; A H W Bruns; R A P Raijmakers; M C H de Groot; T van der Bruggen Journal: Antimicrob Resist Infect Control Date: 2020-05-27 Impact factor: 4.887